NCT00003997 2013-02-086-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous LeukemiaNational Cancer Institute (NCI)Phase 1 Completed25 enrolled